Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 04, 2022

SELL
$57.92 - $72.58 $184,359 - $231,022
-3,183 Closed
0 $0
Q4 2021

Feb 07, 2022

SELL
$64.88 - $73.64 $6,552 - $7,437
-101 Reduced 3.08%
3,183 $231,000
Q3 2021

Nov 08, 2021

BUY
$67.69 - $73.03 $222,293 - $239,830
3,284 New
3,284 $229,000
Q4 2020

Feb 10, 2021

SELL
$56.65 - $64.55 $289,651 - $330,044
-5,113 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$62.1 - $78.08 $34,838 - $43,802
561 Added 12.32%
5,113 $323,000
Q2 2020

Aug 11, 2020

BUY
$72.34 - $84.0 $329,291 - $382,368
4,552 New
4,552 $350,000
Q4 2018

Feb 13, 2019

SELL
$60.54 - $79.0 $182,830 - $238,580
-3,020 Closed
0 $0
Q3 2018

Nov 13, 2018

SELL
$71.28 - $78.92 $101,431 - $112,303
-1,423 Reduced 32.03%
3,020 $233,000
Q2 2018

Aug 13, 2018

SELL
$64.88 - $75.68 $11,483 - $13,395
-177 Reduced 3.83%
4,443 $315,000
Q1 2018

May 15, 2018

SELL
$72.84 - $88.8 $29,136 - $35,520
-400 Reduced 7.97%
4,620 $348,000
Q4 2017

Jan 29, 2018

SELL
$71.15 - $83.52 $89,791 - $105,402
-1,262 Reduced 20.09%
5,020 $360,000
Q3 2017

Nov 13, 2017

BUY
$72.11 - $85.47 $452,995 - $536,922
6,282
6,282 $509,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Northeast Investment Management Portfolio

Follow Northeast Investment Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northeast Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Northeast Investment Management with notifications on news.